Hormonal
Phosphorylation of Perilipin at specific sites (Ser-492 and Ser-517) by PKA is required to release Abhd5, allowing it to interact with and activate Atgl, thereby stimulating lipolysis.
This research identifies the specific molecular 'switch' (PKA phosphorylation of Perilipin) that turns on fat burning. When hormones signal the body to use energy, this switch releases the enzyme (Abhd5) that activates fat breakdown. This underscores the importance of hormonal triggers (like exercise or fasting) in mobilizing stored fat.
Phosphorylation of Plin on serine 492 or serine 517 rapidly releases Abhd5 from Plin, allowing Abhd5 to directly interact with Atgl.
Why this rating
Strong evidence from mutation studies and FRET/BiFC assays showing site-specific requirements.
Source
Perilipin Controls Lipolysis by Regulating the Interactions of AB-hydrolase Containing 5 (Abhd5) and Adipose Triglyceride Lipase (Atgl)
James G. Granneman et al. · Journal of Biological Chemistry · 2009
DOI 10.1074/jbc.m109.068478
More from this paper
- Perilipin (Plin) suppresses basal lipolysis by sequestering the co-activator Abhd5, preventing it from interacting with and activating Adipose Triglyceride Lipase (Atgl).Good
- Knockdown of Abhd5 reduces both basal and stimulated lipolysis, indicating that Abhd5 is essential for triglyceride breakdown independent of Hormone-Sensitive Lipase (HSL).Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →